Dr. Nadel was announced as president of SNMMI for the 2023-2024 term at the 2023 SNMMI annual meeting taking place in Chicago.
Nuclear medicine, like many subspecialties, is facing a workforce crisis. The lack of incoming residents, techs, researchers, and other medical staff is hitting at a particularly poor time, as the role of nuclear medicine and molecular imaging is rapidly expanding with newfound applications in oncology, neurodegenerative disorders, and beyond.
The lack of staffing is top of mind for the Society of Nuclear Medicine and Molecular Imaging's incoming president Helen Nadel, MD, FRCPC, who began her year-long term at this year's SNMMI Annual Meeting, taking place June 24-27, 2023 in Chicago.
Dr. Nadel, who is director of pediatric nuclear medicine at Lucile Packard Children’s Hospital at Stanford and clinical professor of radiology at the Stanford School of Medicine, told Diagnostic Imaging that recruitment efforts are in full effect, with targeted programs being rolled out that focus on early education opportunities. For instance, the society held an information fair for interested high school students during the annual meeting, where children and their parents were welcome to tour exhibits and learn more about the specialty.
Dr. Nadel and other SNMMI leadership are also focused on boosting the profile of nuclear medicine, molecular imaging, and theranostics globally by partnering with other organizations and associations in the space to produce best practice guidelines and appropriate use critieria.
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
January 24th 2025In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
PET Agent Gets FDA Fast Track Designation for Cardiac AL and ATTR Amyloidosis
January 22nd 2025Previously approved for the detection of neuritic beta amyloid plaque, the PET agent (18F)florbetaben is currently being evaluated in a phase 3 multicenter trial for the diagnosis of cardiac amyloidosis.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.